These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 30256922)
1. Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Hakki M; Humphries RM; Hemarajata P; Tallman GB; Shields RK; Mettus RT; Doi Y; Lewis JS Clin Infect Dis; 2019 May; 68(12):2045-2052. PubMed ID: 30256922 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Dominance of Carbapenem-Non-Susceptible Zhang L; Tan FC; Strasfeld L; Hakki M; Kirienko NV Front Cell Infect Microbiol; 2022; 12():904602. PubMed ID: 35782141 [TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study. Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109 [TBL] [Abstract][Full Text] [Related]
4. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676 [TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Hocquet D; Berthelot P; Roussel-Delvallez M; Favre R; Jeannot K; Bajolet O; Marty N; Grattard F; Mariani-Kurkdjian P; Bingen E; Husson MO; Couetdic G; Plésiat P Antimicrob Agents Chemother; 2007 Oct; 51(10):3531-6. PubMed ID: 17682106 [TBL] [Abstract][Full Text] [Related]
6. Carbapenem nonsusceptibility with modified Choudhury D; Talukdar AD; Choudhury MD; Maurya AP; Chanda DD; Chakravorty A; Bhattacharjee A Indian J Med Microbiol; 2017; 35(1):137-139. PubMed ID: 28303836 [TBL] [Abstract][Full Text] [Related]
8. Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients. Gottesdiener LS; Satlin MJ Transpl Infect Dis; 2023 Nov; 25 Suppl 1(Suppl 1):e14169. PubMed ID: 37864309 [TBL] [Abstract][Full Text] [Related]
9. Transcriptional Analysis of MexAB-OprM Efflux Pumps System of Pseudomonas aeruginosa and Its Role in Carbapenem Resistance in a Tertiary Referral Hospital in India. Choudhury D; Das Talukdar A; Dutta Choudhury M; Maurya AP; Paul D; Dhar Chanda D; Chakravorty A; Bhattacharjee A PLoS One; 2015; 10(7):e0133842. PubMed ID: 26221722 [TBL] [Abstract][Full Text] [Related]
10. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa. Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499 [TBL] [Abstract][Full Text] [Related]
11. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa. Ray GT; Baxter R; DeLorenze GN Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150 [TBL] [Abstract][Full Text] [Related]
12. Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey. Trecarichi EM; Giuliano G; Cattaneo C; Ballanti S; Criscuolo M; Candoni A; Marchesi F; Laurino M; Dargenio M; Fanci R; Cefalo M; Delia M; Spolzino A; Maracci L; Bonuomo V; Busca A; Principe MID; Daffini R; Simonetti E; Dragonetti G; Zannier ME; Pagano L; Tumbarello M; Int J Antimicrob Agents; 2023 Jun; 61(6):106806. PubMed ID: 37030470 [TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Wolter DJ; Smith-Moland E; Goering RV; Hanson ND; Lister PD Diagn Microbiol Infect Dis; 2004 Sep; 50(1):43-50. PubMed ID: 15380277 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections. Teresa Tejedor M; Martín JL; Navia M; Freixes J; Vila J Vet Microbiol; 2003 Jul; 94(4):295-301. PubMed ID: 12829383 [TBL] [Abstract][Full Text] [Related]
15. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762 [TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of the oprD porin gene by a novel insertion sequence ISPa195 associated with large deletion in a carbapenem-resistant Pseudomonas aeruginosa clinical isolate. Bocharova Y; Savinova T; Shagin DA; Shelenkov AA; Mayanskiy NA; Chebotar IV J Glob Antimicrob Resist; 2019 Jun; 17():309-311. PubMed ID: 30684654 [TBL] [Abstract][Full Text] [Related]
18. Acquired fluoroquinolone resistance genes in corneal isolates of Pseudomonas aeruginosa. Khan M; Summers S; Rice SA; Stapleton F; Willcox MDP; Subedi D Infect Genet Evol; 2020 Nov; 85():104574. PubMed ID: 32992031 [TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Eagye KJ; Banevicius MA; Nicolau DP Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824 [TBL] [Abstract][Full Text] [Related]
20. High-level resistance to meropenem in clinical isolates of Pseudomonas aeruginosa in the absence of carbapenemases: role of active efflux and porin alterations. Chalhoub H; Sáenz Y; Rodriguez-Villalobos H; Denis O; Kahl BC; Tulkens PM; Van Bambeke F Int J Antimicrob Agents; 2016 Dec; 48(6):740-743. PubMed ID: 28128097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]